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Introduction {#sec001}
============

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a newly discovered positive-sense single-stranded RNA coronavirus known as SARS-CoV-2. It was first recognized in Wuhan, Hubei province, China, in December 2019 \[[@pone.0238417.ref001], [@pone.0238417.ref002]\]. As of 11 August 2020, a total of 19,936,210 confirmed cases of SARS-CoV-2 infection and over 732,499deaths have been reported globally \[[@pone.0238417.ref003]\]. In Malaysia, 9,103 cases and 125 deaths have been reported on 11 August 2020. Approximately 52% of all cases were from the densely populated Klang Valley, which comprises of the Federal Territories of Kuala Lumpur and Putrajaya as well as the state of Selangor \[[@pone.0238417.ref004]\]. The symptoms of SARS-CoV-2 infection are non-specific, but are usually characterized by fever, generalized weakness and dry cough \[[@pone.0238417.ref002], [@pone.0238417.ref005]\]. Most patients with COVID-19 have a mild or moderate illness and recover from the disease without needing special treatment. However, the disease can result in severe clinical manifestations and death. Thus far, the elderly or individuals with underlying medical conditions (such as chronic lung disease, diabetes, or serious heart conditions), have been observed to be more vulnerable to severe disease outcomes with COVID-19 \[[@pone.0238417.ref002]\].

As the COVID-19 outbreak developed into a pandemic, the WHO has recommended robust diagnostic testing to differentiate SARS-CoV-2 from other routine respiratory infections to aid in guiding appropriate clinical management. In response to the COVID-19 pandemic, Malaysia announced a nationwide movement control order (MCO) from 18 March 2020 including measures such as quarantine, isolation, social distancing, and community containment as part of efforts to curb the pandemic. Intensive contact tracing, together with increased capacity for weekly viral detection, were employed with the aim of enabling the country to resume normal day-to-day activities and operations as soon as possible. Despite efforts to increase the nationwide capacity for SARS-CoV-2 testing, including enlisting laboratory in universities, both public and private, it was overwhelmed by huge number of samples collected for testing. For example, in its daily reporting on 6 April 2020, the Crisis Preparedness and Response Centre (CPRC), Ministry of Health (MoH) infographic showed that 55,566 individuals have been tested but 8,109 results were still pending \[[@pone.0238417.ref006]\].

Shortage of consumables especially the RNA extraction kits because of global demand for testing, further contributed to the delay and efficiency of testing. Sample pooling, a strategy deployed for early comprehensive screening of influenza viruses and the human immunodeficiency virus (HIV) \[[@pone.0238417.ref007]\] and now for SARS-CoV-2 \[[@pone.0238417.ref008]--[@pone.0238417.ref011]\], has been demonstrated to be a cost-effective method to increase viral detection capacity in large scale diagnostic testing as well as for community screening, without compromising on the accuracy of the testing. International Medical University (IMU), a private medical university in Kuala Lumpur, responded to the call for national service by volunteering to perform the SARS-CoV-2 testing to help ease the congestion at the National Public Health Laboratory (NPHL), MoH. Here, we describe a sample pooling method for RNA extraction and qRT-PCR for the detection of SARS-CoV-2 as an alternative method to increase the cost-effectiveness of SARS-CoV-2 diagnostic tests as well as laboratories' capacity for viral detection.

As we did not perform pooled testing modelling and we were using different testing kits interchangeably, we performed a series of experiments to determine the framework for pooled testing in our laboratory. In preliminary pooled testing on clinical samples, we determined the group size for pooled testing, and followed by comparison of pooled and individual testing on clinical specimens to determine that the sensitivity of pooled testing is comparable to individual testing. We then use the validated pooled testing on the prospective clinical specimens.

Materials and methods {#sec002}
=====================

Specimen type and processing {#sec003}
----------------------------

Clinical Nasopharyngeal/Oropharyngeal (NP/OP) swab specimens used in this study were submitted to the NPHL. These specimens were from close contacts of qRT-PCR confirmed COVID-19 cases, collected in the community and primary care clinics throughout the nation. Clinical NP/OP swab specimens in viral transport media (VTM) were transported on ice to the IMU, where all specimens were refrigerated and processed within 24 hours upon receipt of the specimens. As part of national service, IMU provided the testing service to ease the congestion at the NPHL. IMU followed the diagnostic protocol provided by NPHL and report back to NPHL the results of the testing.

Sample pooling approach with various nucleic acid extraction kits {#sec004}
-----------------------------------------------------------------

For this study, a total of 6 clinical specimens with a range of C~T~ values that previously tested positive for SARS-CoV-2 by qRT-PCR was selected. Two specimens (H1-H2) demonstrated C~T~ values in the range of 10 to 20, two (M1-M2) had C~T~ values of 21 to 30, and another two (L1-L2) had C~T~ values of 31 to 40. DNeasy Blood and Tissue Kit (Qiagen, Germany) and Viral Nucleic Acid Extraction Kit II (Geneaid Biotech Ltd, Taiwan) were used for nucleic acid extraction. To determine the minimum specimen volume required for the detection of SARS-CoV-2, clinical specimens of volumes 25 μL (10 specimens/pool), 40 μL (5 specimens/pool), 60 μL (10 specimens/pool) and 100 μL (5 specimens/pool) were used in the pooled samples. Nucleic acid extraction of the pooled samples was performed using both extraction kits with adjusted ratio of volume of lysis buffer to sample volume, respectively. Washing steps were performed according to the manufacturer's instructions. The extracts were eluted in 30 μL of RNase-free water and qRT-PCR was performed in triplicate for each purified nucleic acid.

Nucleic acid extraction {#sec005}
-----------------------

Extraction of nucleic acid from clinical NP/OP swab specimens in VTM was performed using either DNeasy Blood and Tissue Kit (Qiagen, Germany) or Viral Nucleic Acid Extraction Kit II (Geneaid Biotech Ltd, Taiwan). For the extraction of individual samples, nucleic acid was extracted from 200 μL of VTM using either extraction kit according to the manufacturers' instructions. For pooled nucleic acid extraction, 10 specimens were pooled together. A volume of 60 μL of VTM from each 10 specimens was pooled together for nucleic acid extraction using either extraction kit with adjusted ratio of lysis buffer to the pooled sample volume. The washing steps were performed according to the manufacturers' instructions. During the final elution step, 30 μL of RNase-free water were used to elute the purified nucleic acid.

Real-time reverse transcription polymerase chain reaction (qRT-PCR) {#sec006}
-------------------------------------------------------------------

Detection of SARS-CoV-2 was performed using the qRT-PCR with primers (RdRp_SARSr-F and RdRp_SARSr-R) targeting the RNA-dependent RNA polymerase (RdRP) gene as described in the WHO-Charité protocol \[[@pone.0238417.ref012]\] ([S1 Table](#pone.0238417.s001){ref-type="supplementary-material"}). The reverse transcription and amplification reaction were performed using the SuperScript™ III One-Step RT-PCR System with Platinum™ Taq DNA Polymerase (Invitrogen, USA). Each 20 μL reaction contained 8.5 μL of RNA template, 10.0 μL of 2× reaction buffer, 0.5 μL of reverse transcriptase/Taq mixture from the kit and 1.0 μL of 10 μM RdRP-Primer/Probe mixture. All oligonucleotides were synthesized by Integrated DNA Technologies (Iowa, USA). The thermal cycling conditions used were 55°C for 15 min for reverse transcription, followed by 95°C for 2 min and then 45 cycles of 95°C for 15 s and 56°C for 30 s. A pool or sample was considered positive for COVID-19 if the C~T~ value was less than or equal to 38.

Preliminary pooled testing of clinical specimens {#sec007}
------------------------------------------------

The pooled testing approach relies on the assumption that the result of the pooled sample correlates to the result of the second set of individual tests. In this case, all individuals from negative pools are considered negative for COVID-19. For the positive pools, each clinical specimen will be re-extracted individually and tested with qRT-PCR again to determine the individual specimen(s) that are positive.

To pilot test out this strategy, 15 pooled samples (10 specimens in each pool) were carried out from 150 retrospective samples (144 negative and 6 positive clinical specimens). The 6 positive specimens were randomly added into 5 different pools. Sixty μL of VTM from each specimen were pooled together for nucleic acid extraction. Pooled specimens (600 μL per pool) were extracted with DNeasy Blood and Tissue kit (Qiagen, Germany) with adjusted 600 μL of lysis AL buffer volume and 600 μL of absolute ethanol for extraction, and the purified nucleic acid was eluted with 30 μL of RNase-free water, followed by testing using one-step real-time qRT-PCR \[[@pone.0238417.ref012]\]. For any pool with positive qRT-PCR results, individual specimens were extracted separately, and qRT-PCR assay was performed. The personnel performing the procedures of nucleic acid extraction and qRT-PCR were blinded from knowing which of the pools had positive samples.

Comparison of pooled testing and individual specimen testing {#sec008}
------------------------------------------------------------

To investigate the sensitivity of pooled testing and individual specimen testing, individual nucleic acid extraction for each specimen (n = 175) was performed in parallel with the 18 pooled samples (17 pools with 10 specimens each, and 1 pool with 7 specimens) prior to the qRT-PCR assay. To ensure extraction efficiency, a known positive sample was also spiked into one of the pools. PCR was performed in triplicate for each sample.

Prospective specimens screening using sample pooling method {#sec009}
-----------------------------------------------------------

A total of 195 pooled samples (n = 1,745) were performed on prospective clinical NP/OP swab specimens. Each pool consists of 10 or less specimens and extracted with adjusted ratio of lysis buffer to the pooled sample volume. The subsequent procedure for nucleic acid extraction and qRT-PCR assay were performed as described above.

Data analysis {#sec010}
-------------

Real-time RT-PCR results were interpreted as recommended in the WHO-Charité protocol \[[@pone.0238417.ref012]\]. A pool or sample was considered positive for COVID-19 if the threshold cycle (C~T~) value was less than or equal to 38.

Ethical statement {#sec011}
-----------------

This study has obtained ethical clearance from the International Medical University Joint Research and Ethical Committee (EC/IRB Ref. No. 4.41/JCM-196/2020). All clinical specimens used in this study were fully anonymised and deidentified by assigning new laboratory reference number before the researchers can access them. The researchers were blinded from the patients' information.

Results {#sec012}
=======

Comparison of different volumes for sample pooling {#sec013}
--------------------------------------------------

While maintaining the sensitivity of qRT-PCR detection of SARS-CoV-2, we investigated the minimal volume of specimen required for the assay. Clinical specimens of different volumes, 25 μL (10 specimens/pool), 40 μL (5 specimens/pool), 60 μL (10 specimens/pool) and 100 μL (5 specimens/pool) were used. One positive specimen was included in each pool and mixed with negative specimens. We used positive specimens with different range of C~T~ values, H1 and H2 (C~T~ values 10--20), M1 and M2 (C~T~ values 20--30), and L1 and L2 (C~T~ values 30--38) to ensure that the pooled testing does not reduce the sensitivity of SARS-CoV-2 detection by qRT-PCR for clinical specimens with low viral loads.

Positive signals were detected in pooled samples using 25 μL, 40 μL, 60 μL and 100 μL of specimen volume for H1, H2, M1 and M2 ([Table 1](#pone.0238417.t001){ref-type="table"}). However, such a trend was not observed for pooled samples using L1 and L2. Pooled samples with 60 μL and 100 μL of L1 and L2 showed positive signals while those with 25 μL and 40 μL of specimen volume resulted in negative signals. We observed that C~T~ values of positive and negative signals from positive and negative samples, respectively, did not vary between the nucleic acid extracted with either the Qiagen DNeasy Blood and Tissue Kit and Geneaid Viral Nucleic Acid Extraction Kit II (Tables [1](#pone.0238417.t001){ref-type="table"} and [S2](#pone.0238417.s002){ref-type="supplementary-material"}).

10.1371/journal.pone.0238417.t001

###### Effect of clinical specimen volume in pooled samples for the detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by qRT-PCR.

![](pone.0238417.t001){#pone.0238417.t001g}

  Specimen ID                                   Volume of specimen used (μL)                  C~T~ value[^*a*^](#t001fn001){ref-type="table-fn"}   
  --------------------------------------------- --------------------------------------------- ---------------------------------------------------- --------------
  H1 (IMU0094)                                  100[^*b*^](#t001fn002){ref-type="table-fn"}   18.35 (0.41)                                         18.25 (0.19)
  60[^*c*^](#t001fn003){ref-type="table-fn"}    21.21 (0.30)                                  22.41 (0.54)                                         
  40[^*b*^](#t001fn002){ref-type="table-fn"}    21.85 (0.33)                                  22.33 (1.02)                                         
  25[^*c*^](#t001fn003){ref-type="table-fn"}    22.08 (0.56)                                  22.51 (0.68)                                         
  H2 (IMU0093)                                  100[^*b*^](#t001fn002){ref-type="table-fn"}   18.61 (0.32)                                         19.25 (0.27)
  60[^*c*^](#t001fn003){ref-type="table-fn"}    20.88 (0.21)                                  20.78 (0.40)                                         
  40[^*b*^](#t001fn002){ref-type="table-fn"}    22.48 (0.44)                                  22.61 (0.59)                                         
  25[^*c*^](#t001fn003){ref-type="table-fn"}    23.43 (1.01)                                  24.22 (1.20)                                         
  M1 (IMU0047)                                  100[^*b*^](#t001fn002){ref-type="table-fn"}   22.85 (1.02)                                         22.83 (0.45)
  60[^*c*^](#t001fn003){ref-type="table-fn"}    25.34 (0.31)                                  24.64 (0.32)                                         
  40[^*b*^](#t001fn002){ref-type="table-fn"}    25.87 (0.18)                                  24.93 (0.67)                                         
  25[^*c*^](#t001fn003){ref-type="table-fn"}    25.82 (0.52)                                  26.07 (0.24)                                         
  M2 (IMU0310)                                  100[^*b*^](#t001fn002){ref-type="table-fn"}   27.73 (0.94)                                         28.41 (1.09)
  60 [^*c*^](#t001fn003){ref-type="table-fn"}   28.40 (0.46)                                  28.45 (0.46)                                         
  40[^*b*^](#t001fn002){ref-type="table-fn"}    29.20 (0.30)                                  29.07 (0.78)                                         
  25[^*c*^](#t001fn003){ref-type="table-fn"}    30.44 (0.60)                                  30.21 (1.13)                                         
  L1 (IMU0254)                                  100[^*b*^](#t001fn002){ref-type="table-fn"}   31.58 (0.44)                                         31.70 (1.02)
  60[^*c*^](#t001fn003){ref-type="table-fn"}    32.25 (0.41)                                  34.24 (1.16)                                         
  40[^*b*^](#t001fn002){ref-type="table-fn"}    33.92 (0.66)                                  Not Detected                                         
  25[^*c*^](#t001fn003){ref-type="table-fn"}    Not Detected                                  Not Detected                                         
  L2 (IMU0255)                                  100[^*b*^](#t001fn002){ref-type="table-fn"}   35.40 (0.16)                                         34.95 (0.92)
  60[^*c*^](#t001fn003){ref-type="table-fn"}    35.74 (0.39)                                  36.11 (0.16)                                         
  40[^*b*^](#t001fn002){ref-type="table-fn"}    Not Detected                                  Not Detected                                         
  25[^*c*^](#t001fn003){ref-type="table-fn"}    Not Detected                                  Not Detected                                         

^*a*^ The C~T~ values are expressed as mean (standard deviation); A pool or sample was considered positive for COVID-19 if the C~T~ value was less than or equal to 38.

^*b*^ The volume of specimen used in 5-sample pool (1 positive + 4 negatives).

^*c*^ The volume of specimen used in 10-sample pool (1 positive + 9 negatives).

Proof of concept with retrospective samples {#sec014}
-------------------------------------------

Based on [Table 1](#pone.0238417.t001){ref-type="table"}, 60 μL of VTM were chosen to pilot test the concept of pooling strategy. Clinical specimens previously established as positive for the *RdRP* gene target of SARS-CoV-2 were chosen to determine whether they were detectable when mixed with negative specimens. Pools of 10 clinical specimens were examined, with four pools containing one positive and nine negative specimens. One pool contained two positives with eight negative specimens. Positive specimens with a different range of C~T~ values were chosen, and PCR was performed in triplicate for determination of reproducibility. The mean C~T~ value of the pooled specimen was compared to the mean C~T~ value of the positive specimen diluted in VTM. The results showed differences of one to two C~T~ demonstrating the effectiveness of pooling 10 specimens ([Table 2](#pone.0238417.t002){ref-type="table"}). We also noted positive C~T~ values on amplification of pooled samples for groups H and I even though no C~T~ values were detected on the first and second time qRT-PCR on individual samples from these two groups.

10.1371/journal.pone.0238417.t002

###### Preliminary testing of sample pooling method on retrospective samples for the detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by qRT-PCR.

![](pone.0238417.t002){#pone.0238417.t002g}

  Pool ID                                  Pooled samples (10 specimens/pool)[^*b*^](#t002fn002){ref-type="table-fn"}   Results of qRT-PCR[^*a*^](#t002fn001){ref-type="table-fn"} (C~T~ value)   
  ---------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------- ---------------------
  A                                        1 positive (IMU0255) + 9 negatives                                           C~T~ = 36.24 (1.35)                                                       C~T~ = 37.54 (0.40)
  B                                        10 negatives                                                                 Not Detected                                                              Not Detected
  C                                        10 negatives                                                                 Not Detected                                                              Not Detected
  D                                        10 negatives                                                                 Not Detected                                                              Not Detected
  E                                        1 positive (IMU0094) + 9 negatives                                           C~T~ = 17.59 (0.90)                                                       C~T~ = 22.36 (0.22)
  F                                        10 negatives                                                                 Not Detected                                                              Not Detected
  G                                        2 positives (IMU0254 & IMU0256) + 8 negatives                                C~T~ = 31.24 (0.36)                                                       C~T~ = 36.40 (1.04)
  C~T~ = 37.49 (0.49)                                                                                                                                                                             
  H[\*](#t002fn004){ref-type="table-fn"}   10 negatives                                                                 Not Detected                                                              C~T~ = 39.46 (0.57)
  I[\*](#t002fn004){ref-type="table-fn"}   10 negatives                                                                 Not Detected                                                              C~T~ = 40.38 (0.60)
  J                                        1 positive (IMU0448) + 9 negatives                                           C~T~ = 30.02 (0.33)                                                       C~T~ = 31.39 (0.29)
  AA                                       10 negatives                                                                 Not Detected                                                              Not Detected
  BB                                       10 negatives                                                                 Not Detected                                                              Not Detected
  CD                                       10 negatives                                                                 Not Detected                                                              Not Detected
  DD                                       10 negatives                                                                 Not Detected                                                              Not Detected
  EE                                       1 positive (IMU0139) + 9 negatives                                           C~T~ = 37.06 (0.32)                                                       C~T~ = 37.70 (0.17)

^*a*^ The qRT-PCR was performed in triplicates; The C~T~ values are expressed as mean (standard deviation); A pool or sample was considered positive for COVID-19 if the C~T~ value was less than or equal to 38.

^*b*^ All clinical NP/OP swab specimens used were previously tested for SARS-CoV-2 (n = 150); Six clinical specimens with a range of C~T~ values that previously tested positive for SARS-CoV-2 by qRT-PCR assay were used to spike the pools.

^*c*^ The volume of clinical specimen used for pooled testing (10-sample pool) is 60 μL.

\* C~T~ values of 39.46 and 40.38 were detected for Groups H and I, respectively. These results were regarded as negative for COVID-19 in this case.

Comparison of individual and pooled testing in parallel {#sec015}
-------------------------------------------------------

To address whether inter-performer variation may be one of the factors contributing to detectable viral load sample pooling, individual sampling and pooled sampling were performed in parallel. As the maximum testing capacity for the laboratory was 100 individual specimens per day, the individual versus pooled testing experiment was performed over a period of two days. One positive sample was implanted among each sample group (N = 89 + 86, these numbers represent tests performed over two separate days) that was collected prospectively. This study demonstrated that pooled sampling detection was comparable to individual sampling ([S3 Table](#pone.0238417.s003){ref-type="supplementary-material"}). Positive signals that were detected among the pools of positive samples were identified to be the implanted positive samples. It was noted that pooled negative samples did not result in a detectable C~T~ value among the prospective samples.

Sampling pooling---the way onwards {#sec016}
----------------------------------

A total of 195 pools composed of 1745 individual specimens were screened ([Fig 1](#pone.0238417.g001){ref-type="fig"}), and 36 positive specimens were identified. Thirty-four positive specimens were identified through pooled screening on Day 6 (April 18, 2020) belonging to a new COVID-19 cluster of students returning to Malaysia from Indonesia on April 16, 2020 \[[@pone.0238417.ref013], [@pone.0238417.ref014]\]. Clinical NP/OP swab specimens were collected in VTM on April 17, 2020 and sent to the laboratory on April 18, 2020 for the screening of COVID-19.

![Number of clinical specimens tested for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\
Testing was performed by pooled sample screening at the IMU Advanced Microbiology Collaborative Research Laboratory since April 13, 2020 ([S1 Dataset](#pone.0238417.s004){ref-type="supplementary-material"}). Each pool included 10 clinical NP/OP swab specimens. A total of 195 pools comprising of 1,745 clinical specimens was screened; \* There was no specimen received for testing on Day 8 (April 20, 2020) and Day 14 (April 26, 2020).](pone.0238417.g001){#pone.0238417.g001}

Discussion {#sec017}
==========

The detection of COVID-19 using qRT-PCR with the pooling of samples during nucleic acid extraction greatly reduced workload and costs especially when disease prevalence was low \[[@pone.0238417.ref015], [@pone.0238417.ref016]\]. In the present study, the cost reduction of RNA extraction without reduction of qRT-PCR sensitivity was achieved by pooling 10 specimens for the initial qRT-PCR screening as described in previous work involving the estimation of HIV and Influenza virus prevalence \[[@pone.0238417.ref016], [@pone.0238417.ref017]\]. The pooling of samples for COVID-19 qRT-PCR was also evaluated by Yelin et al. (2020) \[[@pone.0238417.ref011]\]. Similarly, in this study, pooling was performed on clinical NP/OP swab specimens in VTM, thus allowing a reduction in the number of extractions and qRT-PCRs performed by at least nine-fold. The determination of optimal pool size for each geographical area depends not only on expected prevalence but also on resources available for testing, number of samples available and objective of the testing strategy. When the prevalence is low, such as in Malaysia where the majority of the sample cohort positivity rate was less than 5%, a large proportion of the samples are expected to be negative. Thus, a pooling strategy like this will significantly improve efficiency and will help to reduce the backlog of pending COVID-19 tests, and subsequently reduce diagnostic turn-around-time which is critical for patient management and transmission control (isolation and quarantine measures). It will be useful for resource-strained laboratories especially in developing countries. With this approach, testing may be more feasible and affordable if the government chooses to screen samples from larger communities.

During the Movement Control Order (MCO), Malaysia faced a shortage of both viral RNA extraction and qRT-PCR kits. In addition, with more than 8,000 results still pending during the MCO period, pooled testing was necessarily required. Pooled testing for COVID-19 has been practiced in several laboratories from different regions \[[@pone.0238417.ref008]--[@pone.0238417.ref011]\], with most laboratories practicing pooled testing for qRT-PCR. Here we describe the pooled testing of 10 specimens starting from viral RNA extraction and followed by qRT-PCR while maintaining the reliability of testing. Although we did not perform any modelling on pool size prior to testing, we observed a threshold cycle (C~T~ value) difference of less than 3 between individual and pooled testing ([S2 Table](#pone.0238417.s002){ref-type="supplementary-material"}), and these findings are consistent with recent studies \[[@pone.0238417.ref011]\]. Nevertheless, a previous study conducted by Abdalhamid et al. (2020) has shown that determination of optimal pool size prior to testing was capable of improving the overall efficiency of pooled testing \[[@pone.0238417.ref010]\]. Based on the web-based application for pooling, a pool size with 5 specimens may conserve more resources than a pool size of 10 as the prevalence rate increases.

Noticeable C~T~ values were generated in pools of negative samples (H and I) in retrospective samples ([Table 2](#pone.0238417.t002){ref-type="table"}) at the first round of qRT-PCR. Repeated individual extractions demonstrated that the samples were negative. These results were regarded as negative for COVID-19 in this case. Similar findings were also reported in a recent study based in California, the United States, where one of 292 pools showed a positive E gene signal when screened using qRT-PCR but tested negative when samples from that pool were screened individually \[[@pone.0238417.ref008]\].

Our results suggest that the sample pooling method established herein is a robust and cost-effective strategy for the detection of SARS-CoV-2 in pools of 10 clinical NP/OP swab specimens. Furthermore, two different nucleic acid extraction kits, namely the Qiagen DNeasy Blood and Tissue Kit and Geneaid Viral Nucleic Acid Extraction Kit II, were used in this study interchangeably as we were facing resource limitations during the MCO period in Malaysia. Even though we did not compare the sensitivity and specificity of the two extraction kits, both extraction kits showed consistent results for the detection of positive and negative signals from positive and negative samples, respectively ([S2 Table](#pone.0238417.s002){ref-type="supplementary-material"}).

Our finding is important as it has demonstrated that the nucleic acid extraction kits are interchangeable while the sensitivity remained high for COVID-19 diagnostic test. Till today, many countries are still facing a shortage of COVID-19 testing kits. It is safe to believe that not every laboratory has unlimited supplies of the same testing kits throughout the testing period. Thus, improvisation of protocols may be necessary to overcome such a shortcoming. In general, the use of suggested pooled testing may require validation for effective COVID-19 diagnostic tests as protocols vary from laboratory to laboratory and manufacturer to manufacturer.

The pooled testing strategy used in this study does not require significant structural or workflow changes for laboratories that are currently performing the screening of SARS-CoV-2 by qRT-PCR. However, laboratories are recommended to develop and validate the workflow scheme in-house for the tracking of specimens in pools. This study has a few limitations. Firstly, a reference strain of SARS-CoV-2 and samples that were positive for other respiratory viruses were not included in this study to test for potential inhibitory effects of cellular material from pooling multiple clinical specimens and/or cross-reactivity. Secondly, the pooling approach works well when the disease positivity rate is low. The benefit of pooling, particularly with respect to the conservation of reagents, is nullified if every pool yields a positive result. Thus far (as of 27 April 2020) our laboratory detected 52 positives among the 2,732 samples collected through contract tracing; i.e. a prevalence rate of 1.90%. The pooling approach worked spectacularly well when the prevalence is low. However, as prevalence increased, 5 specimens in a pool may be more practical than 10 specimens. Our data showed that 5-sample pooling versus 10-sample pooling did not show any significant difference in C~T~ value, and thus we chose 10-sample pooling based on the low prevalence rate of positive COVID-19 in our specimens. A threshold cycle (C~T~ value) difference of less than 5 was observed between 5-sample and 10-sample pooling as shown in [Table 1](#pone.0238417.t001){ref-type="table"}. Overall, this study has shown that the pooled screening of COVID-19 has increased overall testing capacity of the COVID-19 with limited resources. Through pooled screening strategy, we were able to increase initial testing capacity, from 100 to 500 specimens in a day.

In summary, we have demonstrated that clinical NP/OP swab specimens in VTM can be pooled and tested for the presence of SARS-CoV-2 without sacrificing sensitivity. Pooled testing is a resource-efficient strategy for the detection of early community transmission of COVID-19.

Supporting information {#sec018}
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Kind regards,

Baochuan Lin, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In your methods section, please disclose the sequences of the RT-PCR primers and ensure that their original source is cited, if applicable. Also, please briefly describe the recommendations of the WHO-Charité protocol in relation to the interpretation of results.

3\. In your ethics statement and methods section, please clarify whether the biological samples used in your study were de-identified and fully anonymized before the researchers accessed them. If not, please clarify whether patients provided consent to use their samples or whether the ethics committee waived the need for consent.

4\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: [http://journals.plos.org/plosone/s/supporting-information](about:blank).

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The purpose of this paper is to develop a specimen pooling procedure that can be used for SARS-CoV-2 detection in samples. The procedure is validated with known positive specimens and also applied in clinical practice. Overall, I think this is an important contribution and should be published subject to minor revisions.

My comments about the paper are as follows.

1\) "Pooling" goes by a few other different names: pooled testing and group testing. It would be good to include these names as key words or include somewhere else in the paper so that search engines can find this paper.

2\) The application of pooling to test for SARS-CoV-2 has many papers already, where most are available on pre-print servers like MedRxiv and ArXiv. The only peer-reviewed papers that I am aware of that use actual specimens are

• Abdalhamid et al. (American Journal of Clinical Pathology, 2020), <https://academic.oup.com/ajcp/article/153/6/715/5822023>

• Hogan et al. (Journal of the American Medical Association, 2020), <https://jamanetwork.com/journals/jama/fullarticle/2764364>

• Lohse et al. (Lancet Infectious Diseases, 2020), <https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30362-5/fulltext>

• Yelin et al. (Clinical Infectious Diseases, 2020), <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa531/5828059>

The Yelin et al. (2020) paper is already mentioned and differences between it and the submitted paper are described. The paper is now published, so its reference should be updated. The Hogan et al. (2020) paper is mentioned as well, but differences between it and the submitted paper need to be described. For the other two papers, you should include them, while also describing how their work differs with the submitted paper.

3\) There are a number of separate investigations performed in the paper, and it was difficult to keep track of them all through initial readings. Overall, I see three main investigations:

a\) "Preliminary testing of sample pooling method",

b\) "Comparison of sampling pooling and individual specimen testing", and

c\) "Prospective specimens screening using sample pooling method"

In the last paragraph of the introduction, one sentence could be given for each to explain their purpose and what is being done. This will help foreshadow to the reader what to expect in the remainder of the paper. Better linkages between these sections may be helpful too.

4\) Page 9 discusses the different volumes used. While it provides results for M2 and L2, what about the results for H1-H2, M1, and L2?

5\) I am concerned about how standard deviations are represented in Tables 1 and 2 by "mean ± standard deviation". While I have seen this representation in some other publications before, it is actually misleading because a reader may think all values are within a range of mean -- standard deviation and mean + standard deviation or a reader may think this is some type of confidence interval. Better approaches for including standard deviations include "mean (standard deviation)" with a table caption or column header stating something like "mean (standard deviation) of ..." or a separate column in the table for the standard deviations.

6\) Page 11 states "n = 89 + 86" but it is not clear until page 15 why these numbers are given separately like this. I recommend giving a brief explanation on page 11 that these numbers represent tests performed over two separate days.

7\) In the Discussion section, I really liked seeing comments about prevalence and how this can be used to determine an appropriate group size. However, I think more guidance should be given about selecting group size. The statistical literature has many papers on pooling where guidance could be obtained. For example, these papers include Hitt et al. (Statistics in Medicine, 2019) and Kim et al. (Biometrics, 2007). The Abdalhamid et al. (2020) is the only paper on SARS-CoV-2 detection that I am familiar which addresses group size selection while also using actual samples.

8\) The data corresponding to Figure 1 should be made available, perhaps in a format like what is given in Table 3 (each pool is displayed with the positive and negative indicators). Rather than an actual table within the paper, I think a data file would be sufficient. One reason to include the "raw" data rather than only the summarized data as in Figure 1 is that it allows readers to see how often multiple positives occur in the same pool. A summary perhaps could provide this same level of detail with

Number of positives Number of pools

0 1709

1 \_\_\_

2 \_\_\_

...

10 \_\_\_

rather than a data file or table like Table 3. One aspect that would be missing though is the time element. Given only three days of positives, this may not be too much of a loss.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0238417.r002
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We thank the reviewers for their generous comments on the manuscript and have edited the manuscript to address their concerns. Please find attached the detailed responses to the reviewer's comments and the revised version of the manuscript. We have made all necessary amendments and modifications following the reviewers' recommendations.

We truly value and appreciate your opinions and helpful contents in improving the manuscript.
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Click here for additional data file.
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PONE-D-20-12301R1

A novel strategy for community screening of SARS-CoV-2 (COVID-19): Sample pooling method

PLOS ONE

Dear Dr. Voon,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The revised version has showed significant improvement, however, there are still a few issues that need to be addressed (please see specific comments and reviewer\'s comments below).

Specific comments:

1\. Line 100, \"\...transported in cold to\...\" Did the authors mean shipped in ice or dry ice? Transported in cold is very vague, please clarify.

2\. Table 3 can be supplemental table.

Please submit your revised manuscript by Sep 25 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Baochuan Lin, Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I have only a few additional comments. All line references are with respect to the tracked changes version of the paper.

1\) There are a number of references to items from April that could be updated. For example, the number of confirmed cases of SARS-CoV-2 stated was for April 22.

2\) Lines 205-208: Could sigmoidal curves for L1 and L2 be examined to see if potentially more cycles could have been useful? This approach was taken by Yelin et al. (2020).

3\) Lines 295:298: Yelin et al. (2020) also looked at pooling before extraction (see "Pooling Prior to RNA Extraction" subsections). Please change your wording in the discussion section.

4\) Lines 318-320 and reply to referee comments: While modeling for pool sizes prior to implementation was not performed, a reference should be made showing how this could be done. This is an important aspect of pooling to make sure it can be done as efficiently as possible. After all, pooling is being used for efficiency purposes. For example, if a pool size of 5 led to much fewer tests than a pool size of 10, wouldn't a pool size of 5 be better to use then?

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0238417.r004

Author response to Decision Letter 1

12 Aug 2020

We would like express our appreciation to the reviewers for their feedback on the manuscript and have edited the manuscript to address their concerns. Please find attached the detailed responses to the reviewer's comments and the revised version of the manuscript. We have made all necessary amendments and modifications following the reviewers' recommendations.
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PONE-D-20-12301R2

Dear Dr. Voon,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Baochuan Lin, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No
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A novel strategy for community screening of SARS-CoV-2 (COVID-19): sample pooling method

Dear Dr. Voon:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Baochuan Lin

Academic Editor

PLOS ONE
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